A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Combination With Copegus (Ribavirin) in Patients With Chronic Hepatitis C (CHC) Enrolled in a Methadone Maintenance Treatment Program.

This study has been completed.
Information provided by (Responsible Party):
Hoffmann-La Roche
ClinicalTrials.gov Identifier:
First received: July 12, 2004
Last updated: October 1, 2015
Last verified: October 2015
This study will evaluate the safety and tolerability of PEGASYS plus ribavirin in previous intravenous (iv) drug users who have CHC and are currently enrolled in a methadone maintenance treatment program. The anticipated time on study treatment is 1-2 years, and the target sample size is <100 individuals.

Condition Intervention Phase
Hepatitis C, Chronic
Drug: peginterferon alfa-2a [Pegasys]
Drug: ribavirin
Phase 4

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Safety Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Open Label, Multi-center, Randomized Safety, Feasibility and Tolerability Pilot Study of Pegasys® (Peginterferon Alfa-2a) Copegus® (Ribavirin) in Previous Intravenous Drug Users Who Are Currently Enrolled in a Methadone Maintenance Treatment Program.

Resource links provided by NLM:

Further study details as provided by Hoffmann-La Roche:

Primary Outcome Measures:
  • Treatment completion rate\n [ Time Frame: Week 24/48 ] [ Designated as safety issue: No ]
  • AEs, laboratory parameters. [ Time Frame: Throughout study ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Beck Depression Inventory, HQLQ, SVR, biochemical response. [ Time Frame: Throughout study ] [ Designated as safety issue: No ]

Enrollment: 48
Study Start Date: November 2003
Study Completion Date: October 2006
Primary Completion Date: October 2006 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1 Drug: peginterferon alfa-2a [Pegasys]
180 micrograms sc weekly for 24 weeks (G 2/3) or 48 weeks (G 1)
Drug: ribavirin
1000/1200mg po daily for 24 weeks (G 2/3) or 48 weeks (G 1)
Experimental: 2 Drug: peginterferon alfa-2a [Pegasys]
180 micrograms sc weekly for 24 weeks (G 2/3) or 48 weeks (G 1)
Drug: ribavirin
1000/1200mg po daily for 24 weeks (G 2/3) or 48 weeks (G 1)


Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • adult patients at least 18 years of age
  • CHC infection, genotype 1, 2, or 3
  • naive to treatment for CHC infection
  • enrolled in a methadone maintenance program with documented attendance for at least 3 months
  • use of 2 forms of contraception during the study on both men and women

Exclusion Criteria:

  • previous treatment for CHC infection
  • co-infection with human immunodeficiency virus (HIV)
  • current use of IV or other illicit drugs
  • decompensated cirrhosis
  • women who are pregnant or breastfeeding
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00087594

United States, California
San Francisco, California, United States, 94121
United States, Connecticut
Farmington, Connecticut, United States, 06030
United States, Hawaii
Honolulu, Hawaii, United States, 96813
United States, Illinois
Downers Grove, Illinois, United States, 60515
United States, Maryland
Baltimore, Maryland, United States, 21205
United States, New York
New York, New York, United States, 10003
United States, Virginia
Richmond, Virginia, United States, 23249
Sponsors and Collaborators
Hoffmann-La Roche
Study Director: Clinical Trials Hoffmann-La Roche
  More Information

No publications provided

Responsible Party: Hoffmann-La Roche
ClinicalTrials.gov Identifier: NCT00087594     History of Changes
Other Study ID Numbers: ML17251 
Study First Received: July 12, 2004
Last Updated: October 1, 2015
Health Authority: United States: Food and Drug Administration

Additional relevant MeSH terms:
Hepatitis C
Hepatitis C, Chronic
Digestive System Diseases
Flaviviridae Infections
Hepatitis, Chronic
Hepatitis, Viral, Human
Liver Diseases
RNA Virus Infections
Virus Diseases
Peginterferon alfa-2a
Anti-Infective Agents
Antiviral Agents
Immunologic Factors
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Physiological Effects of Drugs
Therapeutic Uses

ClinicalTrials.gov processed this record on February 10, 2016